203
+3.57%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Soiken Holdings
Its shares trade on Tokyo Stock Exchange under the ticker 2385.T. It has been listed since 18 December 2003. In the fiscal year to 30 June 2026, it reported revenue of ¥3.87bn and net income of ¥212.3m. At that date it held total assets of ¥6.85bn and shareholders' equity of ¥6.11bn.
Soiken Holdings Inc. is engaged in the development of biomarkers and assessment systems. The company is headquartered in Toyonaka-Shi, Osaka-Fu. The company went IPO on 2003-12-18. The firm operates in six business segments. The Biological Evaluation System segment is engaged in evaluation test of food and research support of medicine. The Healthcare Support segment is engaged in the provision of service about certain health guidance and healthcare insurance. The Cosmetics segment is engaged in manufacturing and sales of cosmetics. The Dietary Supplements segment is engaged in sales of unique dietary supplements. The Marketing segment is engaged in the marketing research of health supplement and sales of energy drink. The Functional Material Development segment is engaged in development and sales of functional materials, such as lactoferrin.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 18 Dec 2003
- Employees
- 98
- Website
- soiken.com ↗
Leadership
Pay as last reported
- Mr. Kentaro IshigamiChairman of the Board, since 2015
- Mr. Masao SumidaPresident, Representative Director, since 2020
- Mr. Takato OkunoFinance Director, Director, since 2024
- Mr. Tomohiro SuginoPresident of Subsidiary, Director, since 2010
- Dr. Osami KajimotoNon-Executive Director
- Mr. Xu DengIndependent Director
- Mr. Masakazu NakajimaIndependent Director
- Mr. Hiroyuki YamamotoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in six business segments including healthcare, cosmetics, and dietary supplements.
- Headquartered in Toyonaka-shi, Osaka-Fu with 98 employees.
- IPO date is 2003-12-18, indicating long-term market presence.
Weaknesses
- Source description claims the company develops biomarkers, which contradicts the provided sector and industry.
- Website provided is https://www.soiken.com/, but no additional details about the site's functionality are given.
- No specific financial data or performance metrics are provided for analysis.
Opportunities
- Expansion into functional materials development, such as lactoferrin, could drive growth.
- Potential for growth in healthcare support and cosmetics segments due to market demand.
- Marketing research in health supplements may lead to new product opportunities.
Threats
- Contradictory information about the company's business focus may confuse investors.
- Lack of financial data makes it difficult to assess market position and risks.
- No mention of competitors or market trends affecting the company.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.